BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Arsenic trioxide (SDK001) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Arsenic trioxide (SDK001)\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07296445-3116@assetmemo.bio
DTSTAMP:20261121T005739Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Arsenic trioxide (SDK001): Phase 3 readout est. (NCT07296445)
DESCRIPTION:Arsenic trioxide (SDK001)\, phase 3\, Acute Myeloid Leukemia.\n
 Study: A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to 
 Intravenous Arsenic Trioxide in Pharmacokinetics\, Safety\, and Efficacy (
 LATITUDE/SDKARS-301)\nEstimated primary completion: June 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/arsenic-trioxide-sdk001#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07296445
URL:https://assetmemo.bio/drug/arsenic-trioxide-sdk001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
